Eric D. Newman

Improved influenza and pneumococcal vaccination in rheumatology patients taking immunosuppressants using an electronic health record best practice alert

OBJECTIVE To examine whether an electronic health record (EHR) best practice alert (BPA), a clinical reminder to help guideline adherence, improved vaccination rates in rheumatology patients receiving immunosuppressants. Guidelines recommend yearly influenza and pneumococcal vaccination with revaccination for patients age >65 years who are taking immunosuppressive medications. METHODS A vaccination BPA was developed based on immunosuppressant treatment, age, and prior vaccinations. At site 1, a hospital-based academic practice, physicians ordered vaccinations. At site 2, a community-based practice, physicians signed orders placed by nurses. Demographics, vaccination rates, and documentation (vaccination or no administration) were obtained. Chi-square and Fishers exact test analysis compared vaccination and documentation rates for October 1 through December 31, 2006 (preBPA), and October 1 through December 31, 2007 (postBPA). Breslow-Day statistics tested the odds ratio of improvement across the years between the sites. RESULTS PostBPA influenza vaccination rates significantly increased (47% to 65%; P < 0.001), with significant improvement at both sites. PostBPA pneumococcal vaccination rates likewise significantly increased (19% to 41%; P < 0.001). PostBPA documentation rates for influenza and pneumococcal vaccinations also increased significantly. Site 2 (nurse-driven) had significantly higher preBPA vaccination rates for influenza (69% versus 43%; P < 0.001) than pneumococcal (47% versus 15%; P < 0.001). CONCLUSION The use of a BPA significantly increased influenza and pneumococcal vaccination and documentation rates in rheumatology patients taking immunosuppressants. A nurse-driven process offered higher efficacy. An EHR programmed to alert providers is an effective tool for improving quality of care for patients receiving immunosuppressants.

Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients.

Background/Objectives:Several studies have associated hydroxychloroquine use with decreased risk of diabetes mellitus (diabetes) or improved glycemic control in rheumatoid arthritis patients, but the studies were small or used data from self-report. The present study sought to replicate this protective relationship in a health system using electronic health records with laboratory data and physician diagnoses. Methods:This study is a retrospective cohort of 1127 adults with newly diagnosed rheumatoid arthritis and no diabetes within the Geisinger Health System between January 1, 2003, and March 31, 2008. Patients were classified as ever users (n = 333) or never users (n = 794) of hydroxychloroquine. Incident diabetes cases were defined using 2010 American Diabetes Association criteria. Results:The median follow-up times for the ever and never hydroxychloroquine users were 26.0 and 23.0 months, respectively (P = 0.28). The median duration of hydroxychloroquine exposure was 14.0 months. Of the 48 cases developing diabetes during observation, 3 were exposed to hydroxychloroquine at time of development and 45 were nonexposed, yielding incidence rates of 6.2 and 22.0 per 1000 per year (P = 0.03), respectively. In time-varying Cox proportional hazards regression models adjusting for sex, age, body mass index, positive rheumatoid factor and anti-cyclic citrullinated peptide antibodies, erythrocyte sedimentation rate, and nonsteroidal anti-inflammatory drug, glucocorticoid, methotrexate, and tumor necrosis factor &agr; inhibitor use, the hazard ratio for incident diabetes among hydroxychloroquine users was 0.29 (95% confidence interval, 0.09-0.95; P = 0.04) compared with nonusers. Conclusions:Our findings support the potential benefit of hydroxychloroquine in attenuating the risk of diabetes in rheumatoid arthritis patients. Further work is needed to determine its potential preventive role in other groups at high risk for diabetes.

Defining Quality of Care in Rheumatology: The American College of Rheumatology White Paper on Quality Measurement

Introduction In recent years, the American College of Rheumatology (ACR) has focused increasingly on the development, review, dissemination, and implementation of quality measures. To help position rheumatology providers as the leading force in defining the quality of rheumatology care, the ACR convened a Quality Measures White Paper Development Workgroup. This diverse workgroup’s charge included synthesizing the information most relevant to the ACR membership regarding quality measurement. As described in this manuscript, the workgroup ultimately participated in a consensus development initiative to craft a set of criteria for quality measures submitted to the ACR for approval. The criteria are intended to guide measure developers and discourage adoption of subpar measures. This White Paper is written for rheumatologists interested in quality measurement, groups undertaking quality measure development, and policy makers. It is organized into the following main sections: a brief introduction provides context and describes the ACR’s national role and positions; section 1 outlines quality measure domains and reviews measure attributes; and section 2 describes and reports results of an ACR workgroup–led process to develop specific criteria for ACR approval of quality measures.

American college of rheumatology quality indicators for rheumatoid arthritis: Benchmarking, variability, and opportunities to improve quality of care using the electronic health record

OBJECTIVE To measure how rheumatologists across our health system performed with the American College of Rheumatology (ACR) quality indicators (QIs) for rheumatoid arthritis (RA) and methotrexate (MTX) drug safety, and to develop opportunities for improvement. METHODS An electronic health record (EHR) review of 1,062 unique RA patients seen by 15 rheumatologists in a 1-year period was performed. Percentage of each QI met, reasons why the metric was not met, and performance of rheumatologists based on years of experience were evaluated. RESULTS The percentage met was high for QI-2 (RA disease-modifying antirheumatic drug use; 94%), QI-3 (intervention if RA worse; 85%), and QI-4 (MTX risks discussion; 87%). Percentage met was lower for QI-1 (RA core data set; 69%), QI-5 (MTX baseline studies; 41%), and QI-6 (MTX followup studies; 46%). QI-1 and QI-5 were low due to most physicians missing a single test, and QI-6 was low because of few physicians driving the percentage down. Better QI performance was seen in rheumatologists with <or=10 years versus >10 years of experience for QI-1 (90% versus 64%; odds ratio [OR] 4.21, P = 0.004) and QI-3 (96% versus 82%; OR 4.47, P = 0.019). EHR chart review for this population required 179.3 hours. CONCLUSION Measurement allows us to better understand the quality of care that we deliver. In this systematic benchmarking of the ACR QIs in a large RA cohort, performance was excellent in RA treatment-related QIs. Significant variability was noted in RA and MTX monitoring measures, which can be addressed using process redesign techniques.

Touchscreen questionnaire patient data collection in rheumatology practice: development of a highly successful system using process redesign.

While questionnaires have been developed to capture patient‐reported outcomes (PROs) in rheumatology practice, these instruments are not widely used. We developed a touchscreen interface designed to provide reliable and efficient data collection. Using the touchscreen to obtain PROs, we compared 2 different workflow models implemented separately in 2 rheumatology clinics.

Improved Bone Health Behavior Using Community Pharmacists as Educators: The Geisinger Health System Community Pharmacist Osteoporosis Education Program

AbstractBackground: Osteoporosis is an exceedingly common, morbid, and potentially fatal disease. Efforts to improve the prevention, diagnosis and treatment of osteoporosis in people living in Central Pennsylvania were instituted in 1996 by the Geisinger Health System. With a catchment of over 2 million people, over 600 physicians and 50 primary care sites, this physician-led system of healthcare is uniquely positioned to influence the delivery of healthcare. Objective: To determine whether the pilot Community Pharmacist Osteoporosis Education Program, a specific project of the osteoporosis disease management program by the Geisinger Health System, improved bone health behavior. Methods: The Community Pharmacist Osteoporosis Education Program, focused on physician and allied healthcare provider guidelines, community intervention, bone density testing, and outcomes analysis, can improve bone health. A group of highly motivated community-based pharmacists were educated about menopause and osteoporosis prevention, diagnosis, and treatment. They were provided with a uniform educational program and held classes in the community. Baseline, satisfaction, and follow-up questionnaires were administered. High risk participants received a follow-up telephone encounter. Primary care physicians were notified about the program and their patients’ participation. Results: Approximately 350 women attended the classes. The mean age was 54 years, 99.4% were Caucasian, and 47% had some education beyond high school. One-third had a family history of osteoporosis or fracture. Participants were uniformly satisfied with the course content and class delivery: 74% rated the class as ‘excellent’, 26% as ‘good’. Follow-up questionnaires at 4 to 6 months demonstrated that of those who were not previously doing so, 58% began taking calcium supplements, 32% exercised more, 50% sought the counsel of their primary care physician, 29% obtained a test of bone density, and 33% started a prescription medication for osteoporosis therapy as a result of attending the class. High risk participants were more likely to obtain a test of bone density after the program than were low risk participants. Conclusion: This program demonstrates that community-based pharmacists can serve as a valuable member of the healthcare provider team. An organized program that provides a standard and consistent educational approach, physician communication, and a reminder system led to better bone health behavior in women in the community.

Perspectives on pre-fracture intervention strategies: the Geisinger Health System Osteoporosis Program

In its first decade, the goals of the Geisinger Health System Osteoporosis Program at its inception were to increase awareness, diagnosis, and treatment of osteoporosis and to monitor predefined outcomes. The program was innovative in that it crossed specialties and regions and used guidelines in an effective manner. In addition, success in reducing hip fracture and cost were demonstrated, and it remains one of the few programs today that has done so, as reported by Newman et al. (Osteoporos Int 14:146–151, 2003). The osteoporosis program has now moved from a provider and allied provider empowerment focus to reorganizing our thoughts about how to best manage osteoporosis care across our healthcare system by defining and acting on four major osteoporosis care gaps: (1) at-risk patients do not get tested, (2) tested patients are not accurately risk assessed, (3) high-risk patients do not get treated, and (4) treated patients are not adherent. Results of current internal programs and future steps are discussed.

Decision support improves knowledge, value clarification and informed choice in patients with rheumatoid arthritis

To examine the potential value of a theory‐based, interactive decision support tool in clinical practice for patients with rheumatoid arthritis who are candidates for biologic agents.

Use of Decision Support for Improved Knowledge, Values Clarification, and Informed Choice in Patients With Rheumatoid Arthritis

To examine the potential value of a theory‐based, interactive decision support tool in clinical practice for patients with rheumatoid arthritis who are candidates for biologic agents.

Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures.

Electronic clinical quality measures (eCQMs) rely on computer algorithms to extract data from electronic health records (EHRs). On behalf of the American College of Rheumatology (ACR), we sought to develop and test eCQMs for rheumatoid arthritis (RA).